AngioDynamics (ANGO, $14.81) announces $46 million acquisition of Eximo; issues lower-than-expected guidance
AngioDynamics shares plummeted on Thursday, after the company released its latest guidance for the full-year.
The medical devices maker announced the purchase of Israeli laser company Eximo for $46 million up front, with up to another $20 million conditional upon Eximo meeting its technical and revenue milestones.
Following the acquisition, AngioDynamics now expects earnings for fiscal 2020 to range between 10 cents and 15 cents a share – a range lower than analysts’ expectation of 26 cents.
Angio CEO Jim Clemmer indicated that the acquisition of Eximo would usher in a remarkable, foundational technology for its portfolio in a way that transforms the way caregivers provide treatment to patients with PAD. "The market is ripe for disruption, and the level of precision, safety, and efficiency offered to physicians by this laser technology creates a substantially differentiated alternative to legacy atherectomy devices," Clemmer said.
Separately, the company reported first-quarter earnings of 8 cents a share, which is higher than analysts’ estimate of 4 cents. Its revenue of $66 million, however, came in slightly below the $67.52 million that analysts were expecting.
ANGO's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for ANGO turned positive on October 15, 2025. Looking at past instances where ANGO's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2025. You may want to consider a long position or call options on ANGO as a result. In of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ANGO advanced for three days, in of 269 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 221 cases where ANGO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for ANGO moved out of overbought territory on October 06, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANGO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ANGO broke above its upper Bollinger Band on October 02, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ANGO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.764) is normal, around the industry mean (10.749). P/E Ratio (0.000) is within average values for comparable stocks, (53.998). ANGO's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.856). ANGO has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.016). P/S Ratio (1.635) is also within normal values, averaging (13.101).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANGO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of medical devices used by radiologists, vascular surgeons and other physicians
Industry PharmaceuticalsOther
Advertisement